A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass

Abstract

The frequent use of GCs as a "bridge therapy" in patients with early arthritis does not seem to be associated with relevant loss of bone mass. Moreover, cumulative GC administration might be associated with an increase of juxtaarticular BMD.